The Food and Drug Administration has published a draft guidance on charging for investigational drugs under an investigational new drug application (IND). The draft guidance is being made available for comment purposes only; comments on it are due Oct. 24, 2022.
If/when finalized (the FDA works in mysterious ways, remember), this draft guidance would replace the current 2016 guidance on charging for investigational drugs.